Drug
Dw4421
Dw4421: highest development phase Phase 3, developed by Daewon Pharmaceutical Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Daewon Pharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| DW4421 20mg NCT07931521 | Phase 3 | Erosive Reflux Disease |
Latest
No recent events.
Follow Dw4421 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.